All In Biotech

Drug Trial Radar · NCT03641560

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

A Multicenter Phase 4, Open-label, Single-arm, Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Sep 19, 2018

Primary completion

Feb 20, 2024

Study completion Feb 20, 2024

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Aug 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy. This study also evaluated the effect of enzalutamide on prostate-specific antigen (PSA).

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

  • EnzalutamideDrug

    Enzalutamide was administered orally

  • Androgen deprivation therapy (ADT)Drug

    All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment- Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until 30 days after last dose (Up to 1899 days)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Site IN00002

    Ahmedabad, India

  • Site IN00004

    Hubli, India

  • Site IN00008

    Kolkata, India

  • Site IN00003

    Nashik, India

  • Site IN00007

    Nashik, India

  • Site IN00010

    New Delhi, India

  • Site IN00001

    Pune, India

  • Site IN00011

    Surat, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.